TY - JOUR
T1 - Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer
AU - Jones, Jeremy C.
AU - Ciombor, Kristen K.
AU - Wu, Christina
AU - Bekaii-Saab, Tanios S.
AU - Strickler, John
N1 - Publisher Copyright:
© 2021 UBM Medica Healthcare Publications. All rights reserved.
PY - 2021
Y1 - 2021
N2 - Metastatic colorectal cancer (mCRC) is the second most common cause of cancer-related death worldwide.1 In the mid-1980s, the median overall survival (OS) for patients with mCRC ranged from 10 to 12 months from the time of initial diagnosis.2 In more recent studies, this median has more than doubled and is commonly reported at more than 25 to 30 months.3 These improvements are due, in large part, to the introduction of multiple novel agents during the last 3 decades. Despite these improvements, however, nearly all patients treated with palliative chemotherapy will eventually develop resistance and ultimately succumb to progression of metastatic disease. Understanding the mechanisms by which malignant cells evade treatment could unlock novel therapeutic strategies that overcome resistance and improve survival. In this review, we will discuss some of the drivers of therapeutic resistance in patients with mCRC and present some novel strategies to overcome resistance.
AB - Metastatic colorectal cancer (mCRC) is the second most common cause of cancer-related death worldwide.1 In the mid-1980s, the median overall survival (OS) for patients with mCRC ranged from 10 to 12 months from the time of initial diagnosis.2 In more recent studies, this median has more than doubled and is commonly reported at more than 25 to 30 months.3 These improvements are due, in large part, to the introduction of multiple novel agents during the last 3 decades. Despite these improvements, however, nearly all patients treated with palliative chemotherapy will eventually develop resistance and ultimately succumb to progression of metastatic disease. Understanding the mechanisms by which malignant cells evade treatment could unlock novel therapeutic strategies that overcome resistance and improve survival. In this review, we will discuss some of the drivers of therapeutic resistance in patients with mCRC and present some novel strategies to overcome resistance.
UR - http://www.scopus.com/inward/record.url?scp=85120720230&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120720230&partnerID=8YFLogxK
U2 - 10.46883/ONC.2021.3510.0654
DO - 10.46883/ONC.2021.3510.0654
M3 - Review article
C2 - 34677922
AN - SCOPUS:85120720230
SN - 0890-9091
VL - 35
SP - 654
EP - 655
JO - ONCOLOGY (United States)
JF - ONCOLOGY (United States)
IS - 10
ER -